Mayne Pharma International Pty. Ltd.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Mayne Pharma International Pty. Ltd.
Mayne Pharma and Dr Reddy’s have announced the completion of a deal that will see the Indian company take over the Australian firm’s US generics business.
Dr Reddy’s has struck a deal to pay at least $90m for the US prescription generics portfolio of Mayne Pharma. The transaction covers products including Mayne’s recently-launched rival to NuvaRing.
Mayne Pharma and partner Mithra have announced the launch of their Haloette generic version of NuvaRing in the US, adding further competition to a field that already includes Amneal and Teva as well as Prasco’s authorized generic.
Aesther Healthcare Acquisition extended the deadline to merge with Ocean Biomedical, while Intrinsic Medicine no longer plans to go public by merging with a SPAC. In restructuring news, Otonomy begins liquidation, Celyad cuts last clinical program with cash running out and Clovis files for bankruptcy.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.